China National Pharmaceutical Group 2025 Annual Report Interpretation: Operating Cash Flow Increased 20.88%, Investment Cash Flow Significantly Narrowed

Operating Revenue: Steady Growth and Continuous Expansion

In 2025, China National Pharmaceutical Group Corporation (Sinopharm) achieved operating revenue of 52.468 billion yuan, a year-on-year increase of 3.70%, continuing the steady growth trend in recent years. The company’s leading position in the pharmaceutical distribution sector has been further consolidated.

Quarterly revenue distribution was relatively balanced:

From a business model perspective, distribution sales saw significant growth, with a year-on-year increase of 12.57%, becoming the main driver of revenue growth; direct sales revenue slightly declined, down 0.84% year-on-year; industrial model revenue decreased by 11.76%, mainly due to pressure on subsidiary Guorui Pharmaceutical’s performance.

Net Profit: Slight Decline, Profitability Resilience Highlighted

In 2025, the company reported a net profit attributable to shareholders of 1.997 billion yuan, a slight decrease of 0.18% year-on-year; net profit excluding non-recurring gains and losses was 1.971 billion yuan, down 1.28%. Despite the slight decline, the company’s profitability remained resilient amid industry-wide profit margin compression.

Earnings Per Share: Adjusted Accordingly, Stable Profit Quality

In 2025, basic earnings per share (EPS) was 2.6462 yuan/share, a decrease of 0.18% year-on-year; EPS excluding non-recurring items was 2.6117 yuan/share, down 1.28%, consistent with net profit trends, maintaining stable profit quality.

Cost Control: Significant Results, Structural Optimization Continues

In 2025, total operating expenses were 12.374 billion yuan, down 1.03% year-on-year, demonstrating effective cost management.

Sales Expenses: Sharp Decline, Efficiency Improved

Sales expenses amounted to 725 million yuan, a decrease of 10.01%, mainly due to digital marketing efforts, supply chain efficiency improvements, and reduced technical service fees.

Management Expenses: Slight Increase, Fine-Tuned Control

Management expenses were 465 million yuan, up 0.85%, mainly due to increased depreciation and amortization. The company maintained stable operations while continuing to refine management.

Financial Expenses: Turned Positive, Structural Improvement

Financial expenses were -22 million yuan, a significant improvement from -68 million yuan in the previous year, mainly due to reduced interest income and optimized debt structure, leading to lower interest expenses.

R&D Expenses: Slight Decrease, Focused on Core Areas

R&D expenses were 69 million yuan, down 5.97%, reflecting a focus on core areas and improved input-output efficiency.

R&D Personnel: Stable Team, Optimized Structure

The company’s R&D team comprises 107 personnel, accounting for 3.54% of total staff. Among them, 30% hold master’s degrees or higher, and 85% have undergraduate degrees or above, indicating a high overall educational level. Age-wise, 48.6% are aged 30-40, forming the core R&D force with a reasonable age structure and strong innovation vitality.

Cash Flow: Structural Improvement and Quality Enhancement

In 2025, the company’s cash flow structure showed positive changes, with significant quality improvements.

Operating Cash Flow: Substantial Growth, Enhanced Self-Sustaining Ability

Net cash flow from operating activities was 2.006 billion yuan, up 20.88% year-on-year, mainly due to improved accounts receivable management, faster collections, and optimized procurement and payment cycles, further strengthening cash generation from operations.

Investing Cash Flow: Sharp Narrowing, More Steady Investment

Net cash flow from investing activities was -170 million yuan, a significant narrowing from -2.584 billion yuan in the previous year, mainly due to large investment outlays in the prior year. The current period’s investments are more focused and prudent.

Financing Cash Flow: Reduced Outflows, Structural Optimization

Net cash flow from financing activities was -1.387 billion yuan, a decrease from previous year, reflecting ongoing efforts to optimize capital structure, reduce unnecessary financing costs, and lower financial expenses.

Potential Risks: Challenges and Responses in Industry Transformation

Industry Policy Risks

Reforms in medical insurance payment methods and normalization of volume-based procurement continue to advance, squeezing profit margins of traditional business. The company actively responds by innovating service models and expanding value-added services, such as promoting SPD projects and national negotiation drug landing services.

Market Competition Risks

The concentration of the pharmaceutical distribution industry is increasing, intensifying market competition. Leveraging nationwide networks, comprehensive product resources, and leading positions in麻精药品 (narcotic and psychotropic drugs), the company consolidates its market position while accelerating digital transformation to improve operational efficiency.

Operational Management Risks

Large accounts receivable and inventory levels pose risks of bad debts and devaluation. The company has established comprehensive receivables management mechanisms and intelligent inventory systems to strengthen risk control. In 2025, receivables turnover improved, and inventory devaluation risks were effectively managed.

Executive and Senior Management Compensation: Reasonable Structure, Linked to Performance

In 2025, the compensation structure for directors, supervisors, and senior management was reasonable and closely tied to company performance. Chairman Liu Yuetao received a pre-tax remuneration of 1 million yuan; acting General Manager Liu Yuetao’s total pre-tax remuneration is included in the chairman’s total; Vice Presidents Xiao Zhuoyuan and Tang Lei each received 1.5 million yuan pre-tax; CFO Chen Fei received 1.2 million yuan pre-tax. The compensation levels reflect the company’s emphasis on core management talent and are aligned with annual operational results, with effective incentive and restraint mechanisms.

Click to view the original announcement>>

Disclaimer: The market involves risks; investments should be cautious. This article is automatically generated by an AI model based on third-party data and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to official announcements for actual data. For questions, contact biz@staff.sina.com.cn.